MX377897B - Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. - Google Patents

Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.

Info

Publication number
MX377897B
MX377897B MX2016006179A MX2016006179A MX377897B MX 377897 B MX377897 B MX 377897B MX 2016006179 A MX2016006179 A MX 2016006179A MX 2016006179 A MX2016006179 A MX 2016006179A MX 377897 B MX377897 B MX 377897B
Authority
MX
Mexico
Prior art keywords
capsaicinoid
formulations
methods
administration
manufacturing
Prior art date
Application number
MX2016006179A
Other languages
English (en)
Other versions
MX2016006179A (es
Inventor
Philip J Birbara
Daniel Bucks
Charles A Birbara
Mary Coughlin
Original Assignee
Propella Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/078,253 external-priority patent/US20140142073A1/en
Application filed by Propella Therapeutics Inc filed Critical Propella Therapeutics Inc
Publication of MX2016006179A publication Critical patent/MX2016006179A/es
Publication of MX377897B publication Critical patent/MX377897B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer en este documento formulaciones capsaicinoides y métodos de tratamiento los cuales se pueden utilizar para tratar/atenuar el dolor en mamíferos. Típicamente, la administración es a través de una inyección en un sitio discreto para proporcionar alivio al dolor durante un período de tiempo prolongado. Las formulaciones se administran en un vehículo farmacéuticamente aceptable. Las formulaciones incluyen un agente analgésico en una cantidad suficiente para atenuar los efectos de quemadura e hiperalgésicos de la administración de capsaicinoides. La invención también incluye un método para tratar el dolor por medio de la administración de un corticosteroide seguida por la administración de un capsaicinoide.
MX2016006179A 2013-11-12 2014-11-12 Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. MX377897B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/078,253 US20140142073A1 (en) 2012-11-12 2013-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use
US14/253,660 US20150133561A1 (en) 2013-11-12 2014-04-15 Aqueous based capsaicinoid formulations and methods of manufacture and use
PCT/US2014/065290 WO2015073577A1 (en) 2013-11-12 2014-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use

Publications (2)

Publication Number Publication Date
MX2016006179A MX2016006179A (es) 2016-10-26
MX377897B true MX377897B (es) 2025-03-11

Family

ID=53044318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006179A MX377897B (es) 2013-11-12 2014-11-12 Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.

Country Status (8)

Country Link
US (2) US20150133561A1 (es)
EP (1) EP3068373B1 (es)
JP (1) JP6782636B2 (es)
KR (1) KR102251124B1 (es)
CN (1) CN105960230B (es)
CA (1) CA2930395A1 (es)
MX (1) MX377897B (es)
WO (1) WO2015073577A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3534961A4 (en) * 2016-11-02 2020-05-27 Centrexion Therapeutics Corporation STABLE AQUEOUS INJECTABLE CAPSAICIN FORMULATIONS AND MEDICAL USES THEREOF
AU2018302342B2 (en) 2017-07-20 2024-08-08 Centrexion Therapeutics Corporation Methods and compositions for treatment of pain using capsaicin
JP2021534207A (ja) * 2018-08-24 2021-12-09 セントレクシオン セラピューティクス コーポレイション 膝関節痛の治療のためのカプサイシン連続投薬方法
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
CN113855626B (zh) * 2020-08-07 2023-03-24 北京泰德制药股份有限公司 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用
CN114028540B (zh) * 2021-11-26 2023-10-17 海南鑫开源医药科技有限公司 一种具有镇痛作用的组合物、微针贴片及其制备方法以及应用
WO2025153515A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Lyophilized resiniferatoxin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
JPS63130540A (ja) * 1986-11-18 1988-06-02 Sunstar Inc 鎮痛用組成物
JPH0621063B2 (ja) * 1986-12-06 1994-03-23 サンスタ−株式会社 歯科用鎮痛剤組成物
JP2001515492A (ja) 1997-03-13 2001-09-18 エヌ． キャンベル，ジェイムズ カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔
JP2002124960A (ja) 2000-10-16 2002-04-26 Link Evolution Corp 通信装置、通信システム、及び、通信方法
JP2006513267A (ja) * 2002-12-18 2006-04-20 アルゴルクス ファーマスーティカルズ，インク カプサイシノイドの投与
PT1587506E (pt) 2002-12-18 2008-10-30 Algorx Administração de capasaicinóides
NZ542887A (en) 2003-04-08 2008-05-30 Algorx Pharmaceuticals Inc Preparation and purification of synthetic capsaicin
WO2005117981A1 (en) 2004-06-02 2005-12-15 Sri International Formulations comprising a capsaicinoid a local anesthetic and/or an antipruritic agent for the treatment of pain
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
EP1830836B1 (de) * 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
WO2006069452A1 (de) * 2004-12-28 2006-07-06 Mestex Ag Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
ATE551992T1 (de) 2005-05-27 2012-04-15 Royer Biomedical Inc Bioresorbierbare polymermatrizes und verfahren zu ihrer herstellung und verwendung
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
WO2007070547A2 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
US8889652B2 (en) * 2006-12-06 2014-11-18 Seikagaku Corporation Pharmaceutical agent having long-lasting effect of treating arthritic disorders
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140142073A1 (en) * 2012-11-12 2014-05-22 Api Genesis, Llc Aqueous based capsaicinoid formulations and methods of manufacture and use

Also Published As

Publication number Publication date
CN105960230B (zh) 2022-06-21
JP2016540830A (ja) 2016-12-28
KR20160094952A (ko) 2016-08-10
MX2016006179A (es) 2016-10-26
EP3068373A1 (en) 2016-09-21
US20150133561A1 (en) 2015-05-14
CN105960230A (zh) 2016-09-21
CA2930395A1 (en) 2015-05-21
WO2015073577A1 (en) 2015-05-21
JP6782636B2 (ja) 2020-11-11
US20190142948A1 (en) 2019-05-16
KR102251124B1 (ko) 2021-05-13
EP3068373B1 (en) 2021-06-23

Similar Documents

Publication Publication Date Title
MX377897B (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX387113B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX2017005875A (es) Metodos para tratar enfermedades oculares.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
NZ725006A (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
JOP20130236B1 (ar) تركيبات صيدلانية تشتمل على مثبط b-raf ومثبط egfr ومثبط اختياري لــpi3k alpha
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
EA201590847A1 (ru) Новые ингибиторы rock
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2015011347A (es) Tratamiento sistemico y topico combinado de tejidos con trastorno.
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX2014010989A (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.